



Rx Integrity Update Market Leadership Meeting

Rex Swords
October 2013

©2013 Walgreen Co. All rights reserved.

Walgreens
AT THE CORNER OF **HAPPY** & **HEALTHY**™

Agenda

Accomplishments since the Agreement

- Rx Integrity Website
- Rx Integrity Web Portal
- Ceiling Limits Tool
- Controlled Substance Order (CSO) Override Form
- Electronic DEA 106 Form
- Pharmacist GFD Opportunities Review Tool



Rx Integrity Website

StoreNet

Home

IMPROVE

Patient Care

Drug Info

3rd Party

IC Plus

SIMS

Rx Admin

Rx Ops

Forms

Learn

Non Rx

Tools

Fix

Rx Integrity

• [Overview](#)

DEA:

- [DEA Website](#)
- [DEA Local Office Locations](#)
- [DEA Pharmacists Manual](#)
- [DEA Prescription Records Request](#)
- [DEA Fax Template](#)
- [DEA License Number Validation](#)

Policy and Procedures:

- [Target Drug Good Faith Dispensing](#)
- [Controlled Substance Rxs & Good Faith Dispensing](#)

Forms:

- [TD GFD Checklist](#)
- [Controlled Substance Order Override Form](#)
- [Invalid Prescriber DEA Notification Form](#)

FAQs:

- [How to Complete a CSO Override Form](#)
- [How to Place Orders for C-II thru C-V & PSE](#)
- [DEA Visit Guidelines "Do's and Don'ts"](#)

Continuing Education:

- [Pain Management](#)

Rx Integrity Operations:

- [Rx Integrity Web Portal](#)
- [Contact Rx Integrity](#)

Overview

- Rx Integrity was created to protect and grow Walgreens controlled substance business while transforming community pharmacy to play a greater role in the Opioid Narcotic Epidemic and protect our business against high risk prescribers.
- Rx Integrity is responsible for managing, creating, and maintaining controlled substance dispensing, monitoring and reporting programs including the Good Faith Dispensing (GFD) Policy, and the National Target Drug Good Faith Dispensing (TD GFD) program.
- Rx Integrity identifies and minimizes loss of Company assets and ensures the safety, compliance and security of the ordering and dispensing of controlled substances.
- Rx Integrity will investigate and report potential violations of laws, regulations or Company policy internally and suspicious orders externally to the DEA, State Boards, and other agencies as required.
- Rx Integrity currently owns, makes recommendations, and utilizes the Controlled Substance Order Monitoring System (CSOM) to manage the amount of controlled substance product that is shipped to the stores.

News & Updates

StoreNet > RxOps > Pharmacy Policy and Procedures > Rx Integrity



©2013 Walgreen Co. All rights reserved.

3

Rx Integrity Website

Rx Integrity

- [Overview](#)

DEA:

- [DEA Website](#)
- [DEA Local Office Locations](#)
- [DEA Pharmacists Manual](#)
- [DEA Prescription Records Request](#)
- [DEA Fax Template](#)
- [DEA License Number Validation](#)

Policy and Procedures:

- [Target Drug Good Faith Dispensing](#)
- [Controlled Substance Rxs & Good Faith Dispensing](#)

Forms:

- [TD GFD Checklist](#)
- [Controlled Substance Order Override Form](#)
- [Invalid Prescriber DEA Notification Form](#)

FAQs:

- [How to Complete a CSO Override Form](#)
- [How to Place Orders for C-II thru C-V & PSE](#)
- [DEA Visit Guidelines "Do's and Don'ts"](#)

Continuing Education:

- [Pain Management](#)

Rx Integrity Operations:

- [Rx Integrity Web Portal](#)
- [Contact Rx Integrity](#)

Is the complete resource for:

- DEA and controlled substance information
- GFD & TD GFD Policy & Procedures
- Forms and FAQs
- CEs on pain management
- Web Portal for detailed reporting



©2013 Walgreen Co. All rights reserved.

Visibility into Quantities at Store Level

How do I know where my stores are in relation to the controlled substance limits set?



Ceiling Tool



©2013 Walgreen Co. All rights reserved.

Rx Integrity Web Portal



Welcome **Natasha Polst**

Pharmaceutical Integrity

[Log O](#)

[Home](#)

[About](#)

[GFD Opportunities](#)

[Tools](#)

[Reports](#)

WELCOME TO PHARMACY INTEGRITY WEBSITE

Our Mission

The sharp rise in the abuse of prescription painkillers in recent years has lead health care professionals in all practices to find better ways of ensuring those medications are used only for legitimate medical purposes.

We have taken a number of steps to provide additional guidance and training to our pharmacies on the proper handling of controlled substances. These include enhancements to our ordering processes and inventory management systems. As well as working with practitioners to ensure prescriptions are issued for a legitimate purpose.

We are working to ensure our patients continue to have access to the medications they need while fulfilling our role in reducing the potential abuse of controlled substances.

We firmly believe that addressing prescription drug abuse will require all parties – including leaders in the community, physicians, pharmacies, distributors and regulators – to play a role in finding practical solutions to combatting abuse while balancing patient access to critical medication.

To access ceiling tool


2013 Walgreen Co. All rights reserved. Confidential and proprietary information. For internal use only. Do not print or reprod

WAGMDL00708575

HIGHLY CONFIDENTIAL

P-25700_00006

Ceiling Limits Tool: gives stores, district and markets visibility



Pharmaceutical Integrity

Welcome [User Name] [Log Out](#)

[Home](#) [About](#) [GFD Opportunities](#) [Tools](#) [Reports](#)

Ceiling Limits Tool

[Chain](#) -> [Operation](#) -> [Market](#) -> District

District Summary for [District Name]

Number of Items at the Ceiling	Average Number of Items Per Store
4	0.10



Drugs With the Most Number of Stores at the Ceiling in the District


Drugs With the Most Number of Stores at the Ceiling in the District	Number of Stores at Ceiling
SUBOXONE 2-0.5MG SL FILM +30	1
LYRICA 150MG CAP + 90	1
HYDROCOD-HOMATRO 5-1.5+TAB(CAV)30	1
BUPRENORPH/NAL 8/2MG SL TAB 30	1

Store Breakdown

Store Number	Address	City	State	Items at Ceiling	Items Near Ceiling	Detail of Drugs
[Store]	[Address]	[City]	[State]	3	3	Details
[Store]	[Address]	[City]	[State]	1	7	Details
[Store]	[Address]	[City]	[State]	0	6	Details

Drugs listed may need a CSO form filled out, if more product is needed





Pharmaceutical Integrity

Welcome [User Name] [Log Out](#)

[Home](#) [About](#) [GFD Opportunities](#) [Tools](#) [Reports](#)

Ceiling Limits Tool

Store # [Store Number]

Below is a list of drugs which are at or near the ceiling for your store. If additional product is needed for these drugs, please click the Controlled Substance Order (CSO) override form link below.


Note:

- If a CII does not appear on this list, and you have no open orders, you can create a PDQ up to a quantity of two for that drug.
- If a CIII-V does not appear on this list, and you have no open orders, you can create a Quick Order up to a quantity of two for that drug.

Drug	Ceiling Status
HYDROCOD-HOMATRO 5-1.5+TAB(CAV)30	Over Allocation Limit
ZOLPIDER ER 12.5MG TABS+(ANC) 100	Nearing Allocation Limit
CLONAZEPAM 0.5MG TAB (MYL) + 1000	Nearing Allocation Limit
LORAZEPAM 2MG TAB (SAN) + 500	Nearing Allocation Limit
DAYTRANA 20MG PATCH (NOV) 30	Nearing Allocation Limit
DEXMETHYLPHENIDATE 2.5MG TAB+ 100	Nearing Allocation Limit
DEXMETHYLPHENIDATE 5MG TAB + 100	Nearing Allocation Limit
VYVANSE 80MG CAPS + 100	Nearing Allocation Limit

[Click here to initiate a new Controlled Substance Override request.](#)

If you do not see any information for your store or you are seeing another stores information, Please contact us at: RxIntegrity@Walgreens.com



©2013 Walgreen Co. All rights reserved.

Controlled Substance Order (CSO) Override Form: can now be completed by stores

Controlled Substance Order Quantity Override Form

WIC #: -OR- UPC #: -OR- NDC #: **REQUIRED Search Fields**

Most fields are required, except as indicated.

Order Information

WIC #:

UPC #:

NDC #:

Drug Name/Strength:

Order Quantity (Nbr Packages/Bottles):

WIC, UPC, NDC, and Drug Name/Strength will auto-populate when an item is selected.

Enter the requested **Order Quantity** in total units. **DO NOT** enter in the number of Caps/Tabs/GM's/ML's needed.

Reason

Reason:

- ☐ Buyout/Acquisition
- ☐ Emergency Situation
- ☐ Change in Sales Trend
- ☐ Store Type(on-site, hospice, specialty, etc.)
- ☐ Other

Select **ONE** reason which best describes the situation.

Provide a detailed explanation of this request including Rx sales history, 13-week item movement, current on-hand count, inventory adjustments, etc.:

Provide a detailed explanation for the reason selected. This **required** field should include specifics of why additional product is needed.

Click **Submit** to send Request



©2013 Walgreen Co. All rights reserved. Confidential and proprietary information.
For internal use only.

Approval Process for CSO Override Form

Step1 - **Store**

- Submits the CSO override form for review

Step 2 - **Pharmacy Supervisor**

- Approves the request and sends it to Rx Integrity for review
- Rejects the request and sends it back to the pharmacy

Step 3 - **Rx Integrity**

- Approves or rejects the request
- Allow 48 business hours for your request to be reviewed
- Stores can view the status of the submitted CSO override form on the Rx Integrity Website

We keep documentation on file for all district level approvals



©2013 Walgreen Co. All rights reserved. Confidential and proprietary information.
For internal use only.

DEA 106 Forms

- Previously handled by Regulatory Law
- Transitioned to Rx Integrity
- Form is now electronic
- RXM or RXS completes the form and submits to Rx Integrity
- Rx Integrity approves and forwards electronic copy to the DEA
- Store receives and email with a link to print a copy for their records
- District Loss Prevention Manager automatically receives a copy via email



Rx Integrity Web Portal



Welcome **Natasha Polst**

Pharmaceutical Integrity

[Log O](#)

[Home](#)

[About](#)

[GFD Opportunities](#)

[Tools](#)

[Reports](#)

WELCOME TO PHARMACY INTEGRITY WEBSITE

Our Mission

The sharp rise in the abuse of prescription painkillers in recent years has lead health care professionals in all practices to find better ways of ensuring those medications are used only for legitimate medical purposes.

We have taken a number of steps to provide additional guidance and training to our pharmacies on the proper handling of controlled substances. These include enhancements to our ordering processes and inventory management systems. As well as working with practitioners to ensure prescriptions are issued for a legitimate purpose.

We are working to ensure our patients continue to have access to the medications they need while fulfilling our role in reducing the potential abuse of controlled substances.

We firmly believe that addressing prescription drug abuse will require all parties – including leaders in the community, physicians, pharmacies, distributors and regulators – to play a role in finding practical solutions to combatting abuse while balancing patient access to critical medication.

To access DEA 106 form

2013 Walgreen Co. All rights reserved. Confidential and proprietary information. For internal use only. Do not print or reprod

HIGHLY CONFIDENTIAL

WAGMDL00708580

P-25700_00011

Electronic DEA 106 Form

The screenshot shows the Walgreens Pharmaceutical Integrity website. The header includes the Walgreens logo, 'Family of Companies', 'Pharmaceutical Integrity', and a navigation bar with 'Home', 'About', 'GFD Opportunities', 'Tools' (highlighted with a red box), and 'Reports'. Below the header, the title 'Walgreens CONTROLLED SUBSTANCE THEFT / SIGNIFICANT LOSS' is displayed. The main content area contains instructions for reporting a theft or loss, followed by four steps: 1. Pharmacy Manager or Pharmacist, 2. Loss Prevention, 3. Pharmacy Manager or Pharmacy Supervisor, and 4. Pharmacy Manager or Pharmacy Supervisor. At the bottom, there are two tabs: 'Continue an Incident' and 'Create New Incident'. The 'Continue an Incident' tab shows a form with fields for 'Type the Reference Number:', 'Or:', and 'Search by Store:'. The 'Create New Incident' tab shows a form with fields for 'Store#:', 'Title:', and 'Type:', along with a 'New' button.

Walgreens
Family of Companies Pharmaceutical Integrity Link found under tools

Home About GFD Opportunities **Tools** Reports

Walgreens
CONTROLLED SUBSTANCE THEFT / SIGNIFICANT LOSS

Follow the procedure below upon discovery or suspicion of any controlled substance theft, loss in transit or other significant loss.

Step 1. Pharmacy Manager or Pharmacist
The pharmacy manager, pharmacist or appropriate store management person shall immediately report the loss to the district loss prevention supervisor and pharmacy supervisor.

Step 2. Loss Prevention
Loss Prevention investigates to confirm whether a theft, significant loss or loss in transit of controlled substances has occurred.

Step 3. Pharmacy Manager or Pharmacy Supervisor
Upon confirming that a theft, loss in transit or other significant loss of controlled substances occurred, the pharmacy supervisor, pharmacy manager or, if unavailable, loss prevention supervisor notifies the nearest DEA Diversion office within one business day using the DEA notification form letter. The pharmacy manager must ensure that this form is submitted. Complete the entire form, including the appropriate reason for loss, and print a copy of the completed form.

Step 4. Pharmacy Manager or Pharmacy Supervisor
Fax the completed DEA notification letter to the DEA Diversion office, state board of pharmacy, state controlled substance agency (e.g., BNDD, DPS) if applicable, and Pharmaceutical Integrity team (847-368-6349). Maintain a copy of the completed form at the store (in File #4).

Continue an Incident	Create New Incident
Type the Reference Number: <input type="text"/> <input type="button" value="Continue"/>	Store# <input type="text"/> <input type="button" value="Select Store"/>
Or:	Title: <input type="text"/> <input type="button" value="Choose One"/>
Search by Store: <input type="text"/> <input type="button" value="Search"/>	Type: <input type="text"/> <input type="button" value="Choose One"/>
	<input type="button" value="New"/>

The online DEA 106 form allows:

- Improves ease of use
- Improves efficiency
- Same day loss calculations for all suspected drugs
- Fully tracked
- Streamlines DEA reporting process



©2013 Walgreen Co. All rights reserved.

12

Electronic DEA 106 – Entering a loss

Walgreens

CONTROLLED SUBSTANCE THEFT / SIGNIFICANT LOSS

Incident Number: 1384
Store Number: 4067

Type of Incident: Employee Pilferage
Opened Date: 9/27/2013

Step 1: 24 Hour Notification

Due: 9/28/2013 [Show Form](#)

Your completed DEA 24-hour notification can be viewed by clicking on [Show Form](#). Please review and submit to your local DEA office, whose fax number is on the form, and all agencies with fax numbers listed under the cc's. Once complete, click on the submit button.

I certify that I have completed the above requirements for this incident. [Submit](#)

Step 2: Incident Description

Due: 11/26/2013

Please Enter a Description of the Incident (max 1000 characters):

[Submit](#)

LP Case Report Number: 6797

Step 3: State Specific

There are no state specific policies in effect at this time for your State.

Step 4: Enter Drugs/Audit

Due: 11/26/2013

You must complete Step 1, before entering drugs for the DEA 106 form

Step 5: DEA 106 Form

Due: 11/26/2013

You Must Complete Steps 2, 3 and 4 Before Continuing

[Back](#)

- Form is intuitive
- Each section must be completed before going to the next portion of the form
- A Loss Prevention case number must be included to ensure LP knows about the event before form can be started

Electronic DEA 106 – Drug Audit Portion

Step 4: Enter Drugs/Audit

An Audit Is Required for This Incident, please add drugs below.

- You can remove items after adding them by clicking on the 'Delete' button.
- Items you choose to audit can be removed before reporting to the DEA.
- The audit is completed on a per NDC basis. Counts need to be completed on each NDC/Manufacture, not on a drug family.
- If you are unsure of which drugs you need to audit, please contact LP or Rxinventory for assistance

Drug Name	NDC	Beginning Count	Ending Count	Delete
FENTANYL 50MCG/HR TS (WAT) + 5	00591-3212-72	<input type="text"/>	<input type="text"/>	X
HYDROCOD-APAP 10-325 TAB(WAT)+500	00591-2612-05	<input type="text"/>	<input type="text"/>	X
OXYCONTIN 30MG TAB (REFORM) 100	59011-0430-10	<input type="text"/>	<input type="text"/>	X
OXYCONTIN 40MG TAB (REFORM) 100	59011-0440-10	<input type="text"/>	<input type="text"/>	X
Save				

[Add Drug...](#)

Finished Entering Drugs

Pharmacy enters in drugs, counts from the June annual inventory and the ending actual count, the audit runs in the background to pull sales, purchases and claims



©2013 Walgreen Co. All rights reserved.

14

Rx Integrity Runs the Audit in the background

Step 4: Enter Drugs/Audit

Running Audit

The Audit will be complete within 6 hours. You will receive an email once it's complete. Use Reference Number: 1382 to return here and complete the audit.

Drug Name	NDC	Beginning Count	Ending Count
FENTANYL 50MCG/HR TS (WAT) + 5	00591-3212-72	45	20
HYDROCOD-APAP 10-325 TAB(WAT)+500	00591-2612-05	765	201
OXYCONTIN 30MG TAB (REFORM) 100	59011-0430-10	120	100
OXYCONTIN 40MG TAB (REFORM) 100	59011-0440-10	200	100

Step 4: Enter Drugs/Audit

Selecting Items

The Audit is Complete.

- Please remove the drugs from the list below, using the 'Exclude' button on the right, that you do not want to report to the DEA.
- You can reinclude items by clicking on the 'Include' button on the corresponding row.
- If you need to adjust the reported quantity, you can do so by clicking on 'Adjust Quantity'.
- The details of the audit can be viewed for each drug by clicking on the 'Details' button.
- Once Complete, click on the 'Accept Audit' button to continue.

Follow directions to determine which drugs to include

Items That WILL Be Reported To The DEA

	Drug	NDC	Estimated Loss	Reported Loss	Exclude
Details	FENTANYL 50MCG/HR TS (WAT) + 5	00591-3212-72	9	<input type="text" value="9"/>	X
Details	HYDROCOD-APAP 10-325 TAB(WAT)+500	00591-2612-05	224	<input type="text" value="224"/>	X
Details	OXYCONTIN 30MG TAB (REFORM) 100	59011-0430-10	-2	<input type="text" value="100"/>	X

[Save](#) / [Cancel](#)

Items That WILL NOT Be Reported To The DEA

Drug	NDC	Estimated Loss	Include
OXYCONTIN 40MG TAB (REFORM) 100	59011-0440-10	-204	X

Completed DEA 106



CONTROLLED SUBSTANCE THEFT / SIGNIFICANT LOSS

Incident Number: 1382
Store Number: 4067

Type of Incident: Employee Pilferage
Opened Date: 9/27/2013

Step 1: 24 Hour Notification

Completed [Show Form](#)

Your completed DEA 24hour notification can be viewed by Clicking on [Show Form](#). Please review and submit to your local DEA office, whose fax number is on the form, and all agencies with fax numbers listed under the cc's.

Completed by user Nicholas Leners on 9/27/2013

Step 2: Incident Description

Completed

Description: The employee has been taking items at several stores since 2012. They have taken hydrocodone, oxycodone, and alprazolam. LP investigated and the employee was terminated on 9/1/13.

LP Case Report Number: 54634564

Step 3: State Specific

There are no state specific policies in effect at this time for your State.

Step 4: Enter Drugs/Audit

Completed

	Drug	NDC	Estimated Loss	Reported Loss
Details	FENTANYL 50MCG/HR TS (WAT) - 5	00591-3212-72	9	9
Details	HYDROCOD-APAP 10-325 TAB(WAT)-500	00591-2612-05	224	224
Details	OXYCONTIN 30MCG TAB (REFORM) 100	59011-0430-10	-2	100

Step 5: DEA 106 Form

Completed [Show Form](#)

Your DEA 106 Form has been submitted to RxIntegrity for Review. You will be contacted if any changes are needed, or once the form has been approved.

DEA 106 form completed by user Nicholas Leners on 9/27/2013

Your DEA 106 has been approved and submitted to the DEA on 9/27/2013

Your DEA 106 form can be viewed by clicking on the 'Show Form' button. You must print a copy and keep it for your records in tote #4.

Your DEA 106 form has been printed out and put in tote#4 by user Nicholas Leners on 9/27/2013


[Back](#)



©2013 Walgreen Co. All rights reserved.

- Once complete the RXM or RXS submits the form
- Completed form comes to Rx Integrity for final approval before submission the DEA
- Copy emailed to DLPM automatically

Trend for "Cocktail" dispensing



Since October 2012 we have seen a 22% reduction in the number of patients receiving a cocktail monthly



©2013 Walgreen Co. All rights reserved. Confidential and proprietary information. For internal use only.

I Talk About GFD, but What can I do on a visit?


The GFD Opportunities Report was developed to help district level supervision on store visits. The report will highlight pharmacists and specific prescriptions that were filled recently that can be pulled up at store level for coaching purposes.



RPh GFD Opportunities

Pharmacists show in the tool based on quantity, proportion of prescriptions dispensed and percent paid in cash across multiple categories. These include Hydrocodone, Hydromorphone, Oxycodone, Methadone, Carisoprodol, Alprazolam, C2s and All Controls.

Pharmacists which appear in the 94th or higher percentile in 5 or more categories are included in the report. The resulting number of pharmacists which appear in the report is approximately 1% of all pharmacists.



Example of the data for one Pharmacist:

Drug	Percentile	Sales	Rate	Quantity	Oxy 15/30	Cash PSC
ALPRAZOLAM	100	221	3 %	13,208	0 %	12 %
ALL CONTROLS	99	1832	24 %	111,005	3 %	12 %
HYDROCODONE	97	519	7 %	34,815	0 %	12 %
ALL C2 DRUGS	95	507	7 %	34,931	12 %	5 %
OXYCODONE	94	278	4 %	20,727	22 %	4 %



©2013 Walgreen Co. All rights reserved. Confidential and proprietary information. For internal use only.

Pharmacist GFD Opportunities Report



Welcome **Natasha Polster**

Pharmaceutical Integrity

[Log Out](#)

Home

About

GFD Opportunities

Tools

Reports

WELCOME TO PHARMACY INTEGRITY WEBSITE

Click to access RPh GFD Opportunities

Our Mission

The sharp rise in the abuse of prescription painkillers in recent years has lead health care professionals in all practices to find better ways of ensuring those medications are used only for legitimate medical purposes.

We have taken a number of steps to provide additional guidance and training to our pharmacies on the proper handling of controlled substances. These include enhancements to our ordering processes and inventory management systems. As well as working with practitioners to ensure prescriptions are issued for a legitimate purpose.

We are working to ensure our patients continue to have access to the medications they need while fulfilling our role in reducing the potential abuse of controlled substances.

We firmly believe that addressing prescription drug abuse will require all parties – including leaders in the community, physicians, pharmacies, distributors and regulators – to play a role in finding practical solutions to combatting abuse while balancing patient access to critical medication.

Pharmacist GFD Opportunities Review

District Breakdown:

[Market Map](#)

District Number	District Name	Number of Pharmacists
1	ALPRAZOLAM 2MG TABLETS	13
2	ALPRAZOLAM 2MG TABLETS	11
3	ALPRAZOLAM 2MG TABLETS	8
4	ALPRAZOLAM 2MG TABLETS	7
5	ALPRAZOLAM 2MG TABLETS	4
6	ALPRAZOLAM 2MG TABLETS	3
7	ALPRAZOLAM 2MG TABLETS	0

Pharmacist Summary:

Employee Name	Job Title	Store
ALPRAZOLAM 2MG TABLETS	PHARMACIST SALARIED DRUG STORE	
ALPRAZOLAM 2MG TABLETS	MANAGER PHARMACY DEPARTMENT	
ALPRAZOLAM 2MG TABLETS	MANAGER PHARMACY DEPARTMENT	
ALPRAZOLAM 2MG TABLETS	PHARMACIST SALARIED DRUG STORE	
ALPRAZOLAM 2MG TABLETS	PHARMACIST SALARIED DRUG STORE	
ALPRAZOLAM 2MG TABLETS	MANAGER PHARMACY DEPARTMENT	
ALPRAZOLAM 2MG TABLETS	REGIS PHARMACIST MULTIPLE LOCATIONS-SPECIFIC	
ALPRAZOLAM 2MG TABLETS	REGIS PHARMACIST MULTIPLE LOCATIONS-NON SPEC	
ALPRAZOLAM 2MG TABLETS	MANAGER PHARMACY DEPARTMENT	
ALPRAZOLAM 2MG TABLETS	MANAGER PHARMACY DEPARTMENT	
ALPRAZOLAM 2MG TABLETS	REGIS PHARMACIST MULTIPLE LOCATIONS-NON SPEC	
ALPRAZOLAM 2MG TABLETS	PHARMACIST SALARIED DRUG STORE	
ALPRAZOLAM 2MG TABLETS	PHARMACIST SALARIED DRUG STORE	



Pharmaceutical Integrity

Welcome | [Log Out](#)

[Home](#) [About](#) [GFD Opportunities](#) [Tools](#) [Reports](#)

The scripts below are example for the selected pharmacist. Upper limit is defined as the average daily dose plus 3 standard deviations, which should represent 99% of all doses. Doses above this limit are greater than 99% of all daily doses for this product. Click the Rx Number to view the script image.

Please review the following prescriptions. During your review you may want to assess any of the following:

1. Completion of GFD Checklist for target drugs.
2. Did the pharmacist document reason for any unusual dosing or therapy? ie Patient Comments, Rx Annotations, GFD Checklist.
3. Assess patient profile for appropriateness of therapy or unusual patterns such as doctor shopping.
4. Did pharmacist check PDMP (if available), before filling the prescription?

Rx Nbr	str nbr	drug name	sig	fill sold dt	qty	days supply	reason
ALPRAZOLAM 2MG TABLETS		OXYCODONE 30MG IMMEDIATE REL TABS	TK 1 T PO QID PRN	6/3/2013	120	30	Combination with CARISOPRODOL 350MG TABLETS - 2013-06-03, ALPRAZOLAM 2MG TABLETS - 2013-06-14
ALPRAZOLAM 2MG TABLETS		HYDROCODONE/ACETAMINOPHEN 7.5-500 T	TK 1 T PO QD PRF PAIN	6/17/2013	30	30	Combination with CARISOPRODOL 350MG TABLETS - 2013-06-17, ALPRAZOLAM 0.5MG TABLETS - 2013-06-14
ALPRAZOLAM 2MG TABLETS		OXYCODONE/ACETAMINOPHEN 10-325MG TB	TK 1 T PO Q 6 H PRF PAIN	6/28/2013	120	30	Combination with CARISOPRODOL 350MG TABLETS - 2013-06-28, ALPRAZOLAM 2MG TABLETS - 2013-06-30
ALPRAZOLAM 2MG TABLETS		OXYCONTIN 80MG CONTROLLED REL TABS	TK 1 T PO TID	7/9/2013	90	30	Combination with CARISOPRODOL 350MG TABLETS - 2013-07-09, ALPRAZOLAM 2MG TABLETS - 2013-07-08
ALPRAZOLAM 2MG TABLETS		OXYCODONE/ACETAMINOPHEN 10-325MG TB	TK 1 T PO Q 4 TO 6 H. MAX D IS SIX T.	7/9/2013	180	30	Combination with CARISOPRODOL 350MG TABLETS - 2013-07-09, ALPRAZOLAM 2MG TABLETS - 2013-07-08
ALPRAZOLAM 2MG TABLETS		OXYCODONE 30MG IMMEDIATE REL TABS	TK 2 TS PO Q 6 H PRN	7/12/2013	240	30	Combination with CARISOPRODOL 350MG TABLETS - 2013-07-19, ALPRAZOLAM 2MG TABLETS - 2013-07-12
ALPRAZOLAM 2MG TABLETS		HYDROCODONE/ACETAMINOPHEN 10-325 T	TK 1 T PO BID	7/19/2013	60	30	Combination with CARISOPRODOL 350MG TABLETS - 2013-07-19, ALPRAZOLAM 2MG TABLETS - 2013-07-12
ALPRAZOLAM 2MG TABLETS		OXYCONTIN 80MG CONTROLLED REL TABS	TK 1 T PO TID	8/6/2013	90	30	Combination with CARISOPRODOL 350MG TABLETS - 2013-08-06, ALPRAZOLAM 2MG TABLETS - 2013-08-06



©2013 Walgreen Co. All rights reserved.

21

WAGMDL00708590

HIGHLY CONFIDENTIAL

P-25700_00021

Pharmacist GFD Opportunities Webinar

Webinars will be held with Pharmacy Supervisors later this month

Tool gives visibility into pharmacist's dispensing

Provides recent real examples RXS's can use for coaching

Doesn't mean there was anything wrong in filling the prescription

RXS can look for

- Documentation
- Ensure checklist was completed



©2013 Walgreen Co. All rights reserved.

22

What We Need From You

- Your support in referring your teams back to Rx Integrity when questions from the field arise
- Engage your Rx Integrity Manager as they are available to participate in Market meetings and videoconferences to provide specific market and district information, identify trends, etc.
- Encourage your teams to use the Rx Integrity site as a resource for everything GFD related
- Reiterate that Pharmacy GFD Opportunities Tool is intended as a coaching tool for our pharmacists



Questions?